SMi present theirannual RNAi, miRNA & siRNA: A Focus on Nanotechnology & Delivery Conference to be held on 11th
&12th June 2012 in London.. This
year's event will focus on the utility of nanotechnology to aid the delivery
and development of novel therapeutics in the field of RNAi, miRNA and siRNA and
senior industry executives will present attendees with in depth studies on
targeted exosomes, structure-activity relationships and antisense technologies.
Key Benefits of Attending:
Learn about and consider solutions to the issues
within miRNA therapeutic identification and delivery strategies
Evaluate Novartis and GSK's innovative
strategies to ensure success in effective siRNA delivery
Understand the latest advances in nanotechnology
formulation and process engineering from Sanofi-Aventis
Hear about antisense developments from RiboBio
Pharmaceuticals and the University of Westminster
Discuss current developments in novel RNAi therapeutics with experts form Santaris Pharma, Silence Therapeutics and
Quark Pharmaceuticals
Consider commercialisation
and regulatory strategies in nanotechnology
Network with key industry professionals and forge partnerships with key players in the
field
HEAR KEY PRESENTATIONS FROM EXPERTS IN THE
FIELD:
Structure-activity relationships of chitosan/siRNA nanoparticles
in-vitro and vivo Michael Keller, Senior Fellow,
siRNA Project Leader, Technical Research & Development, Novartis
Nanotech formulation and process engineering Mostafa Nakach, Head of
Pharmaceutical Engineering Group, Sanofi-Aventis
Non-viral delivery of self-amplifying RNA vaccines Andrew Geall, Platform
Technology Leader, Novartis
Human mRNA and miRNA expression profiling following a major skin trauma Paul Wilson, Senior
Investigator, GlaxoSmithKline
